

# Marcel A M Beijk

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6216258/publications.pdf>

Version: 2024-02-01

38  
papers

586  
citations

758635

12  
h-index

610482

24  
g-index

39  
all docs

39  
docs citations

39  
times ranked

893  
citing authors

#	ARTICLE	IF	CITATIONS
1	Transradial access in chronic anticoagulated patients: One step closer to a "radial-first" strategy in all patients. <i>International Journal of Cardiology</i> , 2022, 348, 45-46.	0.8	0
2	Detection of Vulnerable Coronary Plaques Using Invasive and Non-Invasive Imaging Modalities. <i>Journal of Clinical Medicine</i> , 2022, 11, 1361.	1.0	14
3	Clinical course of sinus node dysfunction after thoracoscopic surgery for atrial fibrillation—analysis of the Atrial Fibrillation Ablation and Autonomic Modulation via Thoracoscopic Surgery (AFACT) study. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2021, 60, 185-193.	0.6	2
4	Left internal mammary artery injury and subsequent hypovolemic shock due to a hemothorax after subxiphoid pericardiocentesis in a postoperative cardiac surgery patient. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 2360-2364.	0.2	0
5	Implementation of CT Coronary Angiography as an Alternative to Invasive Coronary Angiography in the Diagnostic Work-Up of Non-Coronary Cardiac Surgery, Cardiomyopathy, Heart Failure and Ventricular Arrhythmias. <i>Journal of Clinical Medicine</i> , 2021, 10, 2374.	1.0	0
6	Cangrelor Use in Routine Practice: A Two-Center Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 2829.	1.0	1
7	Respiration-related variations in Pd/Pa ratio and fractional flow reserve in resting conditions and during intravenous adenosine administration. <i>Catheterization and Cardiovascular Interventions</i> , 2021, , .	0.7	2
8	Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease—AIDA trial substudy. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 89-96.	0.7	4
9	Pulmonary vascular imaging characteristics after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 248-256.	0.3	16
10	Long-Term Performance of the COMBO Dual-Therapy Stent: Results from the REMEDEE Registry. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 567-570.	0.3	3
11	Predicting the outcomes of pulmonary hypertension is a "breath-taking" task. <i>Netherlands Heart Journal</i> , 2020, 28, 623-624.	0.3	0
12	A case report of myocardial infarction with non-obstructive coronary artery disease: Graves™ disease-induced coronary artery vasospasm. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-5.	0.3	3
13	MiR-223-3p and miR-122-5p as circulating biomarkers for plaque instability. <i>Open Heart</i> , 2020, 7, e001223.	0.9	45
14	The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 1189-1198.	0.7	6
15	Three-year clinical outcomes after dual-therapy COMBO stent placement: Insights from the REMEDEE registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 342-347.	0.7	8
16	Early discontinuation of dual antiplatelet therapy in patients treated with the bio-engineered pro-healing sirolimus-eluting (COMBO) stent. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 373-375.	0.3	3
17	Evaluation of clinical outcomes after COMBO stent treatment in patients presenting with acute coronary syndrome. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, E31-E37.	0.7	13
18	Two-year clinical outcomes of patients treated with the dual-therapy stent in a 1000 patient all-comers registry. <i>Open Heart</i> , 2017, 4, e000634.	0.9	13

#	ARTICLE	IF	CITATIONS
19	Clinical outcomes after percutaneous coronary intervention with the COMBO stent versus Resolute Integrity and PROMUS Element stents: a propensity-matched analysis. <i>EuroIntervention</i> , 2017, 13, 1202-1209.	1.4	11
20	Clinical outcomes after bare-metal stenting in diabetic patients with lesions carrying a low risk of restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 26-33.	0.7	3
21	Clinical outcomes after percutaneous or surgical revascularisation of unprotected left main coronary artery-related acute myocardial infarction: a single-centre experience. <i>Heart</i> , 2013, 99, 690-699.	1.2	12
22	Differences in cardiovascular risk factors and clinical outcomes between Western European and Southeast Asian patients treated with the Genous Bio-engineered R stent. <i>Coronary Artery Disease</i> , 2012, 23, 271-277.	0.3	10
23	Applying the National Institute for Clinical Excellence criteria to patients treated with the Genous Bio-engineered R stent: a sub-study of the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits) Tj ETQq1 d.0.784374 rgBT /D	0.7	14
24	Multiple Biomarkers at Admission Significantly Improve the Prediction of Mortality in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2011, 57, 29-36.	1.2	91
25	Significant intimal hyperplasia regression between 6 and 18 months following Genous endothelial progenitor cell capturing stent placement. <i>International Journal of Cardiology</i> , 2011, 147, 289-291.	0.8	6
26	A retrospective analysis of consecutive patients undergoing nonurgent percutaneous coronary intervention comparing bare metal stents with drug-eluting stents using the National Institute for Clinical Excellence criteria. <i>Coronary Artery Disease</i> , 2011, 22, 32-39.	0.3	7
27	Three-Year Clinical Follow-Up of an Unselected Patient Population Treated with the Genous Endothelial Progenitor Cell Capturing Stent. <i>Journal of Interventional Cardiology</i> , 2011, 24, 442-449.	0.5	10
28	One-year clinical outcome in an unselected patient population treated with the Genous endothelial progenitor cell capturing stent. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 809-817.	0.7	12
29	Two-year follow-up of the genous endothelial progenitor cell capturing stent versus the taxus libert stent in patients with De Novo coronary artery lesions with a high risk of restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 78, 189-195.	0.7	38
30	The relationship between the number of preprocedural circulating endothelial progenitor cells and angiographic restenosis following coronary artery stent placement. <i>Heart Asia</i> , 2011, 3, 60-5.	1.1	0
31	Toll-like receptor 4 gene polymorphisms show no association with the risk of clinical or angiographic restenosis after percutaneous coronary intervention. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 544-552.	0.7	8
32	Long-term follow-up after nonurgent percutaneous coronary intervention in unprotected left main coronary arteries. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 1026-1036.	0.7	4
33	Genous endothelial progenitor cell capturing stent vs. the Taxus Libert stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study. <i>European Heart Journal</i> , 2010, 31, 1055-1064.	1.0	106
34	One-year clinical outcome after provisional T-stenting for bifurcation lesions with the endothelial progenitor cell capturing stent compared with the bare-metal stent. <i>Atherosclerosis</i> , 2010, 213, 525-531.	0.4	9
35	Genous endothelial progenitor cell-capturing stent system: a novel stent technology. <i>Expert Review of Medical Devices</i> , 2009, 6, 365-375.	1.4	40
36	p27 <sup>kip1</sup> A Single Nucleotide Polymorphism Is Associated With Restenosis Risk After Coronary Stenting and Modulates p27 <sup>kip1</sup> Promoter Activity. <i>Circulation</i> , 2009, 120, 669-676.	1.6	27

#	ARTICLE	IF	CITATIONS
37	Design and rationale of the TRI-stent Adjudication Study (TRIAS) Program. American Heart Journal, 2009, 158, 527-532.e1.	1.2	14
38	XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent. Expert Review of Medical Devices, 2007, 4, 11-21.	1.4	38